RxDoctor Payments Data

Omar Ali, MD

Interventional Pain Medicine · Springfield, OHNPI 1437545050

Payments from drug & device makers

What this record shows

This record is dominated by grants: $56,250 of the $66,641 with a category attached, or 84.4%. Boston Scientific accounts for 74.3% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2019 at $56,763 and has fallen 97.2% since, to $1,562 in 2025. Among interventional pain medicine clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$66,641in general payments, 2019–2025

Across 338 payments — averaging $197.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$50K
  • Medtronic$11K
  • Vertos Medical, Inc.$1K
  • Abbott$1K
  • Collegium Pharmaceutical, Inc.$505
  • Stryker$406
  • plus $3K from 25 others

What the payments were for

  • Grants$56,25084%
  • Travel & lodging$6391%
  • Food & beverage$9,45214%
  • Education$3000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$66,641 in reported general payments places this provider in the 90th percentile of 67 interventional pain medicine providers in Ohio.

See all interventional pain medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$176,379
Medicare patients
269
Services billed
5,149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen565$14,582
MovantikNaloxegol Oxalate27$11,285
Xtampza ErOxycodone Myristate20$10,186
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen424$8,233
Gabapentin486$6,464
Pregabalin179$4,070
Tizanidine Hcl329$3,838
Naloxone Hcl38$2,277
Lidocaine34$2,163
Celecoxib39$2,155
Oxycodone Hcl126$1,882
Buprenorphine11$1,689
Tramadol Hcl144$1,342
Morphine Sulfate ErMorphine Sulfate64$1,201
Methocarbamol104$969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$505$10,18620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 67 interventional pain medicine providers in Ohio.

Other interventional pain medicine in Springfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →